Sarepta Stock Decline

Order byBest matchMost fresh

Sarepta stock extends decline

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

· 3d · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

· 2d

Sarepta Shares Slide Again as Drugmaker Bows to FDA Pressure to Pause Gene Therapy

· 1d

InnovationRx: Sarepta Blinks In Showdown With FDA

The latest twist in the saga followed a decision by Children’s Hospital Los Angeles to halt use of the drug while it was facing regulatory uncertainty.

· 2d

Sarepta falls after gene therapy maker pauses Elevidys shipments in US

· 2d

Sarepta pares gains as report suggests an ‘arduous’ path for Duchenne drug

2don MSN

Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

10h

Sarepta Therapeutics stock tumbles on concern about FDA study requirements

According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report indicates Sarepta would be required to conduct new studies before any potential market reintroduction.

Hoodline4d

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Nasdaq4y

Why Sarepta Therapeutics Stock Is Crashing Today - Nasdaq

What happenedShares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 50.7% as of 11:11 a.m. EST on Friday. The huge decline came after the biotech announced top-line results late on Thursday ...

Forbes4y

Should You Buy Sarepta Stock At $71? - Forbes

Looking at a longer time period, SRPT stock is actually down 35% from levels seen toward the end of 2018. The decline in stock price over the last two years or so can be attributed to unfavorable ...